Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | SLC26A6 | Q9BXS9 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18406168 | 0.75 | KDM4E (0.98) | KDM4EALDH1A1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL4531480 | 0.73 | ALDH1A1 (0.61) | KDM4EALDH1A1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL4527847 | 0.72 | KMT2A (0.80) | KDM4EALDH1A1KMT2AMAPTMEN1 | |
| SCHEMBL4521552 | 0.71 | MEN1 (0.64) | KDM4EALDH1A1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL4564998 | 0.70 | KMT2A (0.71) | KDM4EALDH1A1KMT2AMAPTMEN1 | |
| SCHEMBL13165004 | 0.70 | MAPT (0.58) | KDM4EALDH1A1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL17084517 | 0.68 | KDM4E (0.84) | KDM4EALDH1A1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL31156484 | 0.68 | ALDH1A1 (0.53) | KDM4EALDH1A1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL4525636 | 0.68 | KMT2A (0.66) | KDM4EALDH1A1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL13164902 | 0.68 | RXFP1 (0.62) | KDM4EALDH1A1KMT2AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227853-A1 | INHIBITORS OF CYCLIC AMP PHOSPHODIESTERASES | TRUSTEES OF BOSTON COLLEGE (US) | 2010-09-09 | — | — | US | disclosed |
| US-20100227853-A1 | INHIBITORS OF CYCLIC AMP PHOSPHODIESTERASES | TRUSTEES OF BOSTON COLLEGE (US) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227853-A1 | INHIBITORS OF CYCLIC AMP PHOSPHODIESTERASES | PDE7A, PDE4A, PDE4C | KDM4E 2476/4885ALDH1A1 2265/4885SLC26A6 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.